• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Natera, Inc. - Common Stock (NQ:NTRA)

    198.93 +5.71 (+2.96%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Natera, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
    From Natera, Inc.
    Via Business Wire
    Natera to Report its Third Quarter Results on November 6, 2025
    From Natera, Inc.
    Via Business Wire
    Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
    From Natera, Inc.
    Via Business Wire
    Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
    From Halper Sadeh LLC
    Via Business Wire
    Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
    From Natera, Inc.
    Via Business Wire
    Natera Named to Fast Company’s Next Big Things in Tech List
    From Natera, Inc.
    Via Business Wire
    Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings
    From Natera, Inc.
    Via Business Wire
    Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
    From Natera, Inc.
    Via Business Wire
    Enrollment Tops 1,600 in Natera’s EXPAND Trial of Single Gene NIPT
    From Natera, Inc.
    Via Business Wire
    Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer
    From Natera, Inc.
    Via Business Wire
    Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows
    From Natera, Inc.
    Via Business Wire
    Natera Provides Update on Patent Litigation with NeoGenomics
    From Natera, Inc.
    Via Business Wire
    Signatera™ Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
    From Natera, Inc.
    Via Business Wire
    Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
    From Natera, Inc.
    Via Business Wire
    Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine
    From Natera, Inc.
    Via Business Wire
    Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation
    From Natera, Inc.
    Via Business Wire
    IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
    From Natera, Inc.
    Via Business Wire
    Natera Reports Second Quarter 2025 Financial Results
    From Natera, Inc.
    Via Business Wire
    Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
    From Natera, Inc.
    Via Business Wire
    Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations
    From Natera, Inc.
    Via Business Wire
    Natera to Report Its Second Quarter Results on August 7, 2025
    From Natera, Inc.
    Via Business Wire
    Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer
    From Natera, Inc.
    Via Business Wire
    PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT
    From Natera, Inc.
    Via Business Wire
    Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
    From Natera, Inc.
    Via Business Wire
    Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
    From Natera, Inc.
    Via Business Wire
    Natera Announces Medicare Coverage for Signatera™ Genome
    From Natera, Inc.
    Via Business Wire
    SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
    From Natera, Inc.
    Via Business Wire
    Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
    From Natera, Inc.
    Via Business Wire
    Natera Reports First Quarter 2025 Financial Results
    From Natera, Inc.
    Via Business Wire
    Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
    From Natera, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.